← back to search

Jan Terje Andersen

Immune Regulation (United Kingdom) · FI
Area of research
Radiology, Nuclear Medicine and Imaging · Molecular Biology
Research interest
Research interests include Monoclonal and Polyclonal Antibodies Research, Glycosylation and Glycoproteins Research, Protein purification and stability, and Blood groups and transfusion.
h-index
47
citations
7,611
works
155
NIH funding
primary concept
Chemistry
email

Recent publications

Putative target antigens of the stereotyped intrathecal B cell response in multiple sclerosis
2026cited by 0position: contributordoi
Structural conservation and expanded functionality of hyper-stable human serum albumin variants
2026cited by 0position: contributordoi
Targeting the Neonatal Fc Receptor in Autoimmune Diseases: Pipeline and Progress.
2025cited by 10position: contributordoi
Enhanced plasma half-life and efficacy of engineered human albumin-fused GLP-1 despite enzymatic cleavage of its C-terminal end.
2025cited by 7position: contributordoi
An intranasal subunit vaccine induces protective systemic and mucosal antibody immunity against respiratory viruses in mouse models.
2025cited by 4position: contributordoi
Identification of a direct interaction between the Fab domains of IgG antibodies and human FcRn upon IgG-FcRn complex formation.
2025cited by 3position: contributordoi
Engineering of anticancer human immunoglobulin A equipped with albumin for enhanced plasma half-life.
2025cited by 2position: contributordoi
Tailored collagen binding of albumin-fused hyperactive coagulation factor IX dictates in vivo distribution and functional properties
Nature Communications 2025cited by 0position: lastdoi
Tailored collagen binding of albumin-fused hyperactive coagulation factor IX dictates in vivo distribution and functional properties.
2025cited by 0position: contributordoi
Human IgG Fc-engineering for enhanced plasma half-life, mucosal distribution and killing of cancer cells and bacteria
Nature Communications 2024cited by 66position: lastdoi
Human IgG Fc-engineering for enhanced plasma half-life, mucosal distribution and killing of cancer cells and bacteria.
2024cited by 42position: contributordoi
Biophysical cartography of the native and human-engineered antibody landscapes quantifies the plasticity of antibody developability.
2024cited by 18position: contributordoi
Systematic benchmarking of mass spectrometry-based antibody sequencing reveals methodological biases
2024cited by 2position: contributordoi
Assessing developability early in the discovery process for novel biologics.
2023cited by 62position: contributordoi
Cytosolic antibody receptor TRIM21 is required for effective tau immunotherapy in mouse models.
2023cited by 56position: contributordoi
Antibody blockade of Jagged1 attenuates choroidal neovascularization.
2023cited by 9position: contributordoi
A pan-SARS-CoV-2-specific soluble angiotensin-converting enzyme 2-albumin fusion engineered for enhanced plasma half-life and needle-free mucosal delivery.
2023cited by 6position: contributordoi
Biophysical cartography of the native and human-engineered antibody landscapes quantifies the plasticity of antibody developability
2023cited by 1position: contributordoi
Clinical Significance of Serum Albumin and Implications of FcRn Inhibitor Treatment in IgG-Mediated Autoimmune Disorders
Frontiers in Immunology 2022cited by 97position: middledoi
Progress and challenges for the machine learning-based design of fit-for-purpose monoclonal antibodies.
2022cited by 91position: contributordoi
In silico proof of principle of machine learning-based antibody design at unconstrained scale.
2022cited by 65position: contributordoi
Generation of Multivalent Nanobody-Based Proteins with Improved Neutralization of Long α-Neurotoxins from Elapid Snakes.
2022cited by 27position: contributordoi
Potent TRIM21 and complement-dependent intracellular antiviral immunity requires the IgG3 hinge.
2022cited by 24position: contributordoi
Biophysical differences in IgG1 Fc-based therapeutics relate to their cellular handling, interaction with FcRn and plasma half-life.
2022cited by 19position: contributordoi
Prevention of Fetal/Neonatal Alloimmune Thrombocytopenia in Mice: Biochemical and Cell Biological Characterization of Isoforms of a Human Monoclonal Antibody.
2022cited by 3position: contributordoi
Breakthrough infections with the omicron and delta variants of SARS-CoV-2 result in similar re-activation of vaccine-induced immunity
2022cited by 1position: contributordoi
A needle-free subunit vaccine platform inducing mucosal and systemic antibody immunity
2022cited by 0position: contributordoi
Titers of antibodies the receptor-binding domain (RBD) of ancestral SARS-CoV-2 are predictive for levels of neutralizing antibodies to multiple variants
2022cited by 0position: contributordoi
Evaluation of the Effects of Remdesivir and Hydroxychloroquine on Viral Clearance in COVID-19 : A Randomized Trial.
2021cited by 89position: contributordoi
Targeting the Notch Signaling Pathway in Chronic Inflammatory Diseases.
2021cited by 86position: contributordoi

Grants

No grants ingested yet.

Frequent collaborators

· 29 papers (2020–2026)Torleif Tollefsrud Gjølberg · Authera AS9 papers (2022–2025)Leo C. James · The University of Sydney8 papers (2019–2025)Victor Greiff · University of Oslo8 papers (2021–2026)Kristin Hovden Aaen · Oslo University Hospital7 papers (2021–2026)Aina Karen Anthi · Oslo University Hospital6 papers (2021–2025)Fridtjof Lund-Johansen · Smerteklinikken6 papers (2021–2025)Terje E. Michaelsen · Norwegian Institute of Public Health5 papers (2019–2024)Inger Sandlie · University of Oslo5 papers (2019–2025)Stian Foss · University of Oslo5 papers (2020–2024)Geir Kjetil Sandve · Statistics Norway5 papers (2021–2024)Rahmad Akbar · University of Oslo5 papers (2021–2024)Sopisa Benjakul · Norwegian University of Science and Technology5 papers (2021–2025)Mari Nyquist-Andersen · Oslo University Hospital4 papers (2023–2025)Igor Snapkow · Oslo University Hospital4 papers (2021–2024)Fulgencio Ruso-Julve · University of Oslo4 papers (2022–2025)Morten Carstens Moe · Oslo University Hospital4 papers (2020–2025)Maria Chernigovskaya · Oslo University Hospital4 papers (2021–2024)Jeannette Nilsen · University of Oslo3 papers (2020–2025)Mirko Pinotti · University of Ferrara3 papers (2020–2025)